Treatment approaches in Gilles de la Tourette syndrome

Brain Res Bull. 1983 Aug;11(2):205-8. doi: 10.1016/0361-9230(83)90192-2.


The neurological disorder Gilles de la Tourette syndrome is most often treated with the receptor blocker haloperidol, which also produces multiple side-effects, including the risk for tardive dyskinesia. In placebo control double-blind studies, two other neuroleptic drugs, fluphenazine and trifluoperazine, were found to be as efficaceous as haloperidol, but with fewer side-effects. In other studies, clonidine was shown to be equally efficaceous with haloperidol, but did not produce adverse central nervous system side-effects. To treat the extrapyramidal side-effects accompanying the treatment of Tourette syndrome with neuroleptic agents, amantadine and benztropine were compared in a crossover study. It was demonstrated that amantadine is a superior agent in treating the side effects of haloperidol treatment in Tourette syndrome. The use of lithium was without significant action upon lessening the tics of Tourette syndrome.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Amantadine / therapeutic use
  • Benztropine / therapeutic use
  • Clonidine / therapeutic use
  • Fluphenazine / therapeutic use
  • Haloperidol / adverse effects
  • Haloperidol / antagonists & inhibitors
  • Haloperidol / therapeutic use
  • Humans
  • Lithium / therapeutic use
  • Tourette Syndrome / drug therapy*
  • Trifluoperazine / therapeutic use


  • Benztropine
  • Trifluoperazine
  • Lithium
  • Amantadine
  • Haloperidol
  • Clonidine
  • Fluphenazine